Myriad Genetics faces a tough year ahead with new policy changes. Learn why MYGN stock has cratered and if it's poised for ...

Under the agreement, Storm will act as an ambassador for the Myriad Genetics Breast Cancer Risk Assessment Program, which features the MyRisk with RiskScore Hereditary Cancer test. The latest ...

Myriad Genetics, Inc. MYGN recently announced an agreement with Hannah Storm, a nationally renowned sports broadcaster who ...

As an ambassador for Myriad's Breast Cancer Risk Assessment Program, Storm will promote the MyRisk® with RiskScore® Hereditary Cancer Test, which evaluates genetic risks for various cancers.

Under the agreement, Storm will act as an ambassador for the Myriad Genetics Breast Cancer Risk Assessment Program featuring the MyRisk® with RiskScore® Hereditary Cancer Test, the first and ...

Storm is a longtime SportsCenter anchor and NBC sports anchor, and host of the podcast“NBA DNA with Hannah Storm.” Her world changed in January 2024, when she was diagnosed with stage zero Ductal ...

Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, announced a study revealing that more patients completed hereditary cancer testing when they used an online ...

As per the deal, Storm will act as an ambassador for the Myriad Genetics Breast Cancer Risk Assessment Program featuring the MyRisk with RiskScore Hereditary Cancer Test, hereditary cancer test ...

Research analysts at Leerink Partnrs boosted their FY2024 EPS estimates for Myriad Genetics in a note issued to investors on Tuesday, January 21st. Leerink Partnrs analyst P. Souda now forecasts that ...

Myriad Genetics (NASDAQ:MYGN – Get Free Report) was upgraded by stock analysts at StockNews.com from a “hold” rating to a ...